I just finishing reading the paper on this compound. I thought I would look at the time line on these kind of drugs. Actually pretty short ph1's. Under 4 months. The ph 2/3's look like total of 3 years. (See Telaprevir VX-950) The field for these drugs is very large, must be the wholly grale of drug discovery. This maybe a potenial area where fragment science plays a role. If you want a very difficult read, try the presentation on ASTX drugs HVC. There are several web pages that actually break down this paper and comminicate what they view as important.
This is the area where protein on protein maybe very beneficial.
Owned ANDS when they were bought by Roche. They had a Hep C drug. Early testing went fast but as you say Hate, Phase 3 takes much longer. Just checked the Roche website and it looks like the Phase 3 on the ANDS drug will last till 2016. Huge market for Hep C. $20B people claim. That is why Gilead paid $11B for Pharmasset. Appears they are in the lead at this point. Believe BMY has an approved drug already.